Is Relay Therapeutics a Buy After Promising Trial Results?

Relay Therapeutics announced promising phase 2 trial results for zovegalisib in treating vascular anomalies, with a 60% volumetric response rate. The clinical-stage biotech has a well-capitalized position with $642 million in cash, a structured path to market including a planned phase 3 trial in early 2027, and a diversified pipeline. However, as a pre-revenue company, it faces significant binary risk dependent on the clinical and regulatory success of its lead therapy.

05/22/2026, 5:30 PM • The Motley Fool

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

Relay Therapeutics priced an underwritten public offering of 22.9 million shares at $12.00 per share, raising approximately $275 million in gross proceeds. The offering is expected to close on May 22, 2026. The clinical-stage biotech company is developing precision medicine therapies, with its lead asset zovegalisib currently in Phase 3 trials for HR+/HER2- metastatic breast cancer and being investigated for PIK3CA-driven vascular anomalies.

05/20/2026, 8:21 PM • GlobeNewswire

Why Relay Therapeutics Stock Popped on Wednesday

Relay Therapeutics stock surged 7.87% on Wednesday following positive Phase 2 results for zovegalisib, a vascular anomalies treatment, which showed 60% patient response rates at 12 weeks—exceeding analyst expectations. Two analysts raised their price targets (Barclays to $27, Citizens JMP to $21) and maintained buy ratings. The gains were partially offset by the company's announcement of a secondary stock offering exceeding $200 million.

05/20/2026, 7:01 PM • The Motley Fool

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

Relay Therapeutics announced promising Phase 2 clinical data for zovegalisib in treating PIK3CA-driven vascular anomalies, demonstrating a 60% volumetric response rate at 12 weeks with strong safety and tolerability profiles supporting chronic dosing. The drug showed clinical improvement in 89% of patients per investigator assessment and 79% per patient assessment, with no treatment discontinuations due to adverse events. Expansion cohorts have opened at 400mg once daily and 300mg twice daily doses.

05/19/2026, 6:00 AM • GlobeNewswire

Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

Relay Therapeutics announced positive clinical data for zovegalisib combined with Pfizer's atirmociclib and endocrine therapy in heavily pre-treated metastatic breast cancer patients, showing 44% ORR with favorable tolerability. The company plans to initiate a Phase 3 frontline trial in early 2027 with a supply agreement in place with Pfizer for atirmociclib.

04/27/2026, 6:00 AM • GlobeNewswire

Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.

Nextech Invest, a Switzerland-based biotech-focused fund, increased its stake in Relay Therapeutics by 855,097 shares (~$6.1 million). The purchase brings Relay to 3.85% of Nextech's portfolio. Relay's stock has surged 197% over the past year, driven by its computational drug discovery platform and clinical-stage pipeline including lead candidates RLY-4008 and RLY-2608.

03/19/2026, 3:03 PM • The Motley Fool

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million

Commodore Capital increased its stake in Spyre Therapeutics by 400,161 shares ($10.46 million) in Q4, bringing its total position to $78.24 million (5.21% of AUM). SYRE stock has surged 63% over the past year, significantly outperforming the S&P 500's 13% gain. The preclinical biotech company, focused on inflammatory bowel disease treatments, has a strong balance sheet with $757 million in cash and expects runway into H2 2028, with six Phase 2 readouts expected in 2026.

02/23/2026, 10:18 AM • The Motley Fool

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%

Commodore Capital reduced its Nuvalent stake by 850,000 shares (worth $83.81 million) in Q4 2025, cutting the position from 9.26% to 3.68% of assets. Despite the sale, Nuvalent shares are up 29% over the past year and the company maintains strong cash runway into 2029 with upcoming FDA catalysts including a PDUFA date for zidesamtinib in September.

02/23/2026, 10:01 AM • The Motley Fool

Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

Relay Therapeutics announced it will report Q4 and full year 2025 financial results on February 26, 2026. The clinical-stage biotech company is developing zovegalisib, a PI3Kα inhibitor currently in Phase 3 trials for HR+/HER2- metastatic breast cancer and PI3Kα-driven vascular anomalies, which recently received FDA Breakthrough Therapy Designation based on robust clinical data.

02/19/2026, 5:55 PM • GlobeNewswire

$207B Market Shift: The Race for Fast Track Approval in Oncology

The FDA has accelerated oncology drug approvals with over 50 approvals in 2025 and increased expedited designations in 2026. Multiple biotech companies are advancing cancer treatments through Fast Track and Breakthrough Therapy designations, targeting high-unmet-need solid tumors. Key developments include Oncolytics' pelareorep showing significant survival benefits in colorectal cancer, Relay's zovegalisib receiving Breakthrough designation for breast cancer, MAIA's ateganosine advancing in lung cancer, Zai Lab's AUGTYRO approval in China, and Arrivent's firmonertinib entering pivotal Phase 3 trials for NSCLC.

02/05/2026, 9:35 AM • Benzinga

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

Relay Therapeutics presented subset analysis data for zovegalisib, a PI3Kα inhibitor, showing promising efficacy in breast cancer patients with various treatment histories, including 10.3-month median progression-free survival across patient groups.

12/12/2025, 7:00 AM • GlobeNewswire

Top 3 Biotech Stocks Capitalizing on the AI Revolution

Three clinical-stage biotech companies are leveraging AI to advance drug discovery and treatment in areas like aging, neuroscience, and oncology, with promising platforms that use machine learning to analyze complex biological data.

11/18/2025, 1:02 PM • Investing

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

Kymera Therapeutics announced the appointment of Brian Adams as Chief Legal Officer, succeeding Ellen Chiniara who is retiring. Adams brings nearly two decades of legal leadership experience in life sciences and will oversee legal, governance, and intellectual property functions.

09/03/2025, 7:00 AM • GlobeNewswire